Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.

MLA

Spelman, Tim, et al. “Comparative Effectiveness of Cladribine Tablets versus Other Oral Disease-Modifying Treatments for Multiple Sclerosis: Results from MSBase Registry.” Multiple Sclerosis Journal, vol. 29, no. 2, Feb. 2023, pp. 221–35. EBSCOhost, https://doi.org/10.1177/13524585221137502.

APA

Spelman, T., Ozakbas, S., Alroughani, R., Terzi, M., Hodgkinson, S., Laureys, G., Kalincik, T., Van Der Walt, A., Yamout, B., Lechner-Scott, J., Soysal, A., Kuhle, J., Sanchez-Menoyo, J. L., Blanco Morgado, Y., Spitaleri, D. L., van Pesch, V., Horakova, D., Ampapa, R., Patti, F., & Macdonell, R. (2023). Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Multiple Sclerosis Journal, 29(2), 221–235. https://doi.org/10.1177/13524585221137502

Chicago

Spelman, Tim, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, et al. 2023. “Comparative Effectiveness of Cladribine Tablets versus Other Oral Disease-Modifying Treatments for Multiple Sclerosis: Results from MSBase Registry.” Multiple Sclerosis Journal 29 (2): 221–35. doi:10.1177/13524585221137502.